Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial

Jagmeet P. Singh, Mary Norine Walsh, Spencer H. Kubo, Angelo Auricchio, Peter Paul Delnoy, Michael R. Gold, Prashanthan Sanders, Jo Ann Lindenfeld, Christopher A. Rinaldi, Steven Ullery

Research output: Contribution to journalLetterpeer-review

4 Citations (Scopus)


The WiSE system is a novel, leadless endocardial system that can provide cardiac resynchronization therapy in patients who cannot be treated with a conventional epicardial left ventricular lead. Safety and efficacy were being evaluated in the pivotal, randomized, double-blind SOLVE-CRT Trial (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy.) The trial was initiated in 2018; however, patient enrollment was significantly impacted by the COVID-19 pandemic necessitating a change in design. This article describes the revised trial and the scientific rationale for the specific changes in the protocol.

Original languageEnglish
Pages (from-to)158-162
Number of pages5
JournalAmerican Heart Journal
Publication statusPublished or Issued - May 2021
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this